News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Astrid Thuerigen

Articles by Astrid Thuerigen

19 Efficacy, Safety, and Quality of Life With Ribociclib + Endocrine Therapy in Elderly Patients With HR+/HER2– Advanced Breast Cancer Across the MONALEESA-2, -3, and -7 Trials

19 Efficacy, Safety, and Quality of Life With Ribociclib + Endocrine Therapy in Elderly Patients With HR+/HER2– Advanced Breast Cancer Across the MONALEESA-2, -3, and -7 Trials

ByLowell Hart,Seock-Ah Im,Sara M. Tolaney, MD, MPH,Mario Campone,Timothy Pluard,Berta Sousa,Gilles Freyer,Thomas Decker,Kevin Kalinsky, MD, MS,Astrid Thuerigen,Melissa Gao,Huilin Hu,Sherko Kümmel

August 9th 2024

12 TIP HARMONIA SOLTI-2101/ AFT-58: A Head-to-Head Phase III Study Comparing Ribociclib (RIB) and Palbociclib (PAL) in Patients (pts) With Hormone Receptor– Positive/HER2-Negative/HER2- Enriched (HR+/HER2−/HER2-E) Advanced Breast Cancer (ABC)

ByLisa A. Carey, MD,Tomas Pascual,Daniel Stover,Astrid Thuerigen,Charles Perou,Eva Ciruelos,Ana Casas,Patty Spears,Estelle Roux,Faye Su,Hullin Hu,Yen-Shen Lu,Sara M. Tolaney, MD, MPH,Ann H. Partridge, MD, MPH,Guillermo Villacampa,Juan Manuel Ferrero-Cafiero,Aleix Prat

April 28th 2023

50 Pooled Exploratory Analysis of Survival in Patients (pts) With HR+/ HER2− Advanced Breast Cancer (ABC) and Visceral Metastases (mets) Treated With Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Trials

ByDenise A. Yardley, MD,Yoon Sim Yap,Hamdy Abdel Azim,Richard De Boer,Mario Campone,Alistair Ring,Michelino De Laurentiis,Joyce A. O’Shaughnessy,Javier Cortes,Yogesh Chattar,Astrid Thuerigen,Juan Pablo Zarate,Liz Santarsiero

April 27th 2023

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Nivolumab/AVD in Untreated Hodgkin Lymphoma

Liquid Biopsies, Blood-Based MCED Tests for Detecting CRC in Young Patients

FDA Grants Fast Track Designation to FG001 for High-Grade Glioma Surgery

Potential Rusfertide Approval May Offer More Control of Polycythemia Vera

Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non–Small Cell Lung Cancer